Quentin M. Anstee BSc(Hons), MBBS, PhD, MRCP(UK), FRCP

Prof Quentin M. Anstee is Pro-Vice-Chancellor of the Faculty of Medical Sciences. He holds the Ruth & Lionel Jacobson Chair in Personalised Medicine and is also an Honorary Consultant Hepatologist in the Liver Unit at the Freeman Hospital, Newcastle.

His translational research has made major contributions across the pathophysiology, natural history, diagnosis, and treatment of Metabolically Dysregulated Associated Steatotic Liver Disease (MASLD), formerly called Non-Alcoholic Fatty Liver Disease (NAFLD). His work has provided key insights into temporal changes in steatohepatitis during disease evolution, identified genetic and epigenetic modifiers of liver disease progression and hepatocellular carcinoma risk, and has substantially advanced the field of biomarker development in liver disease.

He has coordinated several major international research consortia studying pathogenesis and developing/validating accurate biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with MASLD, including: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €47.3 million, 2017-2024). He leads the European MASLD Registry and is the chief investigator of multiple ongoing clinical trials assessing new medical therapies for MASLD. He is an NIHR Senior Investigator and has been named as one of the world’s most influential researchers in the Web of Science list of Highly Cited Researchers, amongst the top 1% of scientists by citation metrics. He is an Associate Editor of the Journal of Hepatology.